Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TDO2 | P48775 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19900045 | 1.00 | IDO1 (0.54) | IDO1CYP2C9CYP2C8CYP3A4TDO2 | |
| SCHEMBL29636319 | 0.89 | IDO1 (0.66) | IDO1CYP2C9CYP2C8CYP3A4TDO2 | |
| SCHEMBL19899840 | 0.84 | IDO1 (0.60) | IDO1CYP2C9CYP2C8CYP3A4TDO2 | |
| SCHEMBL23801409 | 0.83 | IDO1 (0.65) | IDO1CYP2C9CYP2C8CYP3A4TDO2 | |
| SCHEMBL23801504 | 0.83 | IDO1 (0.65) | IDO1CYP2C9CYP2C8CYP3A4TDO2 | |
| SCHEMBL21836418 | 0.81 | IDO1 (0.59) | IDO1CYP2C9CYP2C8CYP3A4TDO2 | |
| SCHEMBL17729194 | 0.81 | IDO1 (0.59) | IDO1CYP2C9CYP2C8CYP3A4TDO2 | |
| SCHEMBL28905180 | 0.81 | IDO1 (0.49) | IDO1CYP2C9CYP2C8CYP3A4TDO2 | |
| SCHEMBL17729117 | 0.81 | IDO1 (0.56) | IDO1CYP2C9CYP2C8CYP3A4TDO2 | |
| SCHEMBL21187176 | 0.80 | IDO1 (0.60) | IDO1CYP2C9CYP2C8CYP3A4TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351164-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210283123-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351164-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2152/4885CYP2C8 709/4885 |
| US-20210283123-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2152/4885CYP2C8 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.